HKEX-listed biotechs. Pipeline valuation anchored to observable licensing transactions, not DCF assumptions.
Take any HKEX biotech that listed since 2018 under Chapter 18A. There is a good chance it now has an approved drug, real revenue, and a licensing deal with a global pharma company sitting on the balance sheet. The market still trades the whole company as if everything depended on one upcoming trial.
That gap is the trade. A licensing deal is not an opinion. It is a price set by a serious buyer after months of diligence. Once you have that number, the rest of the company is not being priced anymore: it is residual. Subtract the deal's value from the market cap and what is left is what the public market pays for everything else: the approved drug, the rest of the pipeline, the platform. That number is usually a fraction of what comparable assets have transacted at. The work is not predicting the trial. The work is finding the companies where a serious buyer has already paid for the trial risk.
AstraZeneca Paid US$100M for One Molecule. The Rest Trades at US$507M.
AstraZeneca quantified the value of one Phase I asset at US$100M upfront, US$1.9B in milestones. Subtract net cash from the US$730M market cap and the rest of the company sits at US$507M. Approved drug, Phase III pipeline, platform: all of it.
← All analyses